Table 2 Data in training cohort
From: Novel model based on ultrasound predict axillary lymph node metastasis in breast cancer
Total | No metastasis | Lymph metastasis | P-value | |
|---|---|---|---|---|
Menopausal | ||||
Premenopausal | 88 (46.1%) | 49 (46.7%) | 39 (45.3%) | 0.88 |
Postmenopausal | 103 (53.9%) | 56 (53.3%) | 47 (54.7%) | |
Location | ||||
Upper-out | 54 (28.3%) | 30 (28.6%) | 24 (27.9%) | 0.31 |
Lower-out | 24 (12.6%) | 12 (11.4%) | 12 (14.0%) | |
Upper inner | 47 (24.6%) | 31 (29.5%) | 16 (18.6%) | |
Lower inner | 52 (27.2%) | 27 (25.7%) | 25 (29.1%) | |
Center | 14 (7.3%) | 5 (4.8%) | 9 (10.5%) | |
Histological grade | ||||
I | 35 (18.3%) | 18 (17.1%) | 17 (19.8%) | 0.86 |
II | 61 (31.9%) | 35 (33.3%) | 26 (30.2%) | |
III | 95 (49.7%) | 52 (49.5%) | 43 (50.0%) | |
Histological type | ||||
Ductal | 177 (92.7%) | 96 (91.4%) | 81 (94.2%) | 0.57 |
Lobular | 9 (4.7%) | 5 (4.8%) | 4 (4.7%) | |
Other | 5 (2.6%) | 4 (3.8%) | 1 (1.2%) | |
ER | ||||
1+ | 29 (15.2%) | 19 (18.1%) | 10 (11.6%) | 0.58 |
2+ | 27 (14.1%) | 15 (14.3%) | 12 (14.0%) | |
3+ | 67 (35.1%) | 37 (35.2%) | 30 (34.9%) | |
Negative | 68 (35.6%) | 34 (32.4%) | 34 (39.5%) | |
PR | ||||
1+ | 27 (14.1%) | 19 (18.1%) | 8 (9.3%) | 0.075 |
2+ | 31 (16.2%) | 18 (17.1%) | 13 (15.1%) | |
3+ | 43 (22.5%) | 17 (16.2%) | 26 (30.2%) | |
Negative | 90 (47.1%) | 51 (48.6%) | 39 (45.3%) | |
Her2 | ||||
Negative | 124 (64.9%) | 69 (65.7%) | 55 (64.0%) | 0.88 |
Positive | 67 (35.1%) | 36 (34.3%) | 31 (36.0%) | |
Ki67 | ||||
<=14 | 32 (16.8%) | 20 (19.0%) | 12 (14.0%) | 0.44 |
>14 | 159 (83.2%) | 85 (81.0%) | 74 (86.0%) | |
P53 | ||||
Negative | 69 (36.1%) | 45 (42.9%) | 24 (27.9%) | 0.035 |
Positive | 122 (63.9%) | 60 (57.1%) | 62 (72.1%) | |
VEGF-C | ||||
Negative | 50 (26.2%) | 36 (34.3%) | 14 (16.3%) | 0.005 |
Positive | 141 (73.8%) | 69 (65.7%) | 72 (83.7%) | |
Regular shape | ||||
Yes | 99 (51.8%) | 48 (45.7%) | 51 (59.3%) | 0.081 |
No | 92 (48.2%) | 57 (54.3%) | 35 (40.7%) | |
Boundary | ||||
Clearly | 87 (45.5%) | 47 (44.8%) | 40 (46.5%) | 0.88 |
Obscure | 104 (54.5%) | 58 (55.2%) | 46 (53.5%) | |
Echo | ||||
Homogeneous | 85 (44.5%) | 46 (43.8%) | 39 (45.3%) | 0.88 |
Heterogeneous | 106 (55.5%) | 59 (56.2%) | 47 (54.7%) | |
Calcification | ||||
No | 95 (49.7%) | 46 (43.8%) | 49 (57.0%) | 0.082 |
Yes | 96 (50.3%) | 59 (56.2%) | 37 (43.0%) | |
Age(years) | 49.9 ± 8.9 | 49.8 ± 8.9 | 50.0 ± 9.0 | 0.87 |
Diameter(cm) | 14.6 ± 5.2 | 12.1 ± 4.2 | 17.7 ± 4.6 | < 0.001 |
Tumor peak systolic flow velocity(PS) | 37.6 ± 6.0 | 38.2 ± 6.4 | 37.0 ± 5.5 | 0.12 |
Tumor end diastolic flow velocity(EDF) | 10.2 ± 2.2 | 10.2 ± 2.1 | 10.2 ± 2.3 | 0.87 |
Tumor systolic velocity to end of diastolic velocity ratio(SD) | 3.9 ± 1.1 | 3.9 ± 1.0 | 3.9 ± 1.3 | 0.36 |
Tumor resistance index(RI) | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.18 |
Tumor pulsatility index(PI) | 1.8 ± 0.3 | 1.8 ± 0.3 | 1.8 ± 0.3 | 0.55 |
lymphatic transverse | 6.0 ± 1.2 | 5.9 ± 1.2 | 6.1 ± 1.3 | 0.34 |
lymphatic longitudinal | 11.8 ± 2.1 | 11.8 ± 2.1 | 11.8 ± 2.0 | 0.98 |
cortex area hilum ratio(CH) | 1.9 ± 0.3 | 1.8 ± 0.2 | 2.0 ± 0.3 | < 0.001 |
Lymph peak systolic flow velocity(PS) | 17.4 ± 6.2 | 15.8 ± 5.7 | 19.4 ± 6.3 | < 0.001 |
Lymph end diastolic flow velocity(EDF) | 7.9 ± 2.1 | 7.8 ± 1.9 | 8.0 ± 2.2 | 0.27 |
Lymph systolic velocity to end of diastolic velocity ratio(SD) | 3.2 ± 1.8 | 2.4 ± 0.8 | 4.2 ± 2.1 | < 0.001 |
Lymph resistance index(RI) | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.34 |
Lymph pulsatility index(PI) | 1.7 ± 0.3 | 1.7 ± 0.3 | 1.7 ± 0.3 | 0.25 |